Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - ISTA Pharmaceuticals (NasdaqNM:ISTA)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
Aug 29Price hit new 52-week low ($1.66)
July 26Conference call: ISTA Pharmaceuticals, Inc. Financial Results (Q2 2001)
Location
15279 Alton Parkway, Building 100
Irvine, CA 92618
Phone: (949) 788-6000
Employees (last reported count): 39
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Related Links
 ·Search Yahoo! for related links...
Ownership
·Insider and 5%+ Owners: 64%
·Over the last 6 months:
 · 2 insider sells; 105.0K shares
  (1.0% of insider shares)
·Institutional: 29% (80% of float)
(28 institutions)
·Net Inst. Buying: 1.24M shares (+21.82%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
ISTA Pharmaceuticals discovers, develops and markets new remedies for diseases and conditions of the eye. Its product development efforts are focused on using highly purified formulations of the hyaluronidase enzyme to treat diseases and conditions such as vitreous hemorrhage, diabetic retinopathy, corneal opacification and keratoconus. Each of these conditions affects a significant number of patients worldwide and can impair vision and potentially cause blindness. ISTA's lead product candidate, Vitrase, a proprietary formulation of hyaluronidase, is designed for the treatment of severe vitreous hemorrhage and diabetic retinopathy.
More from Market Guide: Expanded Business Description

Financial Summary
ISTA Pharmaceuticals discovers and develops new remedies for diseases and conditions of the eye, including vitreous hemorrhage, diabetic retinopathy, corneal opacification and keratoconus. For the six months ended 6/30/01, the Company reported no revenues. Net loss applicable to Common decreased 66% to $10.1 million. Lower loss reflects higher net interest income and the absence of $19.2 million of deemed preferred dividends.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Robert McNeil, Ph.D., 57
Chairman
--  
Edward Danse, 48
Pres, CEO, Director
$291K
J. MacRae, 48
Exec. VP, COO, Chief Financial Officer
239K
Hampar Karageozian, 61
Sr. VP, Discovery and CTO
250K
David Waltz, 49
VP-Fin.
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ISTAAs of 31-Aug-2001
Price and Volume
52-Week Low
on 29-Aug-2001
$1.66 
Recent Price$2.39 
52-Week High
on 5-Sep-2000
$14.625
Daily Volume (3-month avg)23.1K
Daily Volume (10-day avg)16.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-83.6%
52-Week Change
relative to S&P500
-78.0%
Share-Related Items
Market Capitalization$37.3M
Shares Outstanding15.6M
Float5.60M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.98 
Earnings (ttm)-$1.71 
Earnings (mrq)-$0.32 
SalesN/A 
Cash (mrq)$1.06 
Valuation Ratios
Price/Book (mrq)2.45 
Price/EarningsN/A 
Price/SalesN/A 
Income Statements
Sales (ttm)$0 
EBITDA (ttm)-$20.1M
Income available to common (ttm)-$21.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-95.44%
Return on Equity (ttm)-397.63%
Financial Strength
Current Ratio (mrq)5.63 
Debt/Equity (mrq)0 
Total Cash (mrq)$16.5M
Short Interest
As of 8-Aug-2001
Shares Short0 
Shares Short
(Prior Month)
5,000 
Daily Volume14.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.